Compare Newmont Corporation (NEM) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs Recursion Pharmaceuticals Inc — how do they compare? Newmont Corporation trades at $118.27 (market cap $121.75B), while Recursion Pharmaceuticals Inc trades at $4.23 (market cap $2.14B). The key difference: Newmont Corporation is far larger — about 56.9× Recursion Pharmaceuticals Inc's market cap, and Newmont Corporation pays a 0.9% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Newmont Corporation for 58 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| NEM | RXRX | |
|---|---|---|
Market Cap | $121.75B | $2.14B |
Volume | 5,421,125 | 30,789,535 |
Sector | Basic Materials | Health |
52-Week High | $135.14 | $6.79 |
52-Week Low | $78.63 | $2.84 |
Typical Hold Time | 58 Days | 22 Days |
Enterprise Value | $118.34B | $1.66B |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newmont Corporation (NEM) trades at $113.54, down 2.45% over 24 hours, with technical indicators showing a bearish short-term trend. The company reported strong fundamentals, including record free cash flow of $5.3 billion in H1 2026 (Defense World, 2026-10-01) and consistent earnings beats in recent quarters. Revenue grew to $22.67 billion in 2025, with net income margin improving to 31.25%. Analyst sentiment remains positive, with a consensus price target of $136.83 and 76% buy ratings.
The outlook for NEM is supported by robust cash flow generation and operational improvements, but near-term price pressure exists from technical bearish signals and gold price volatility. Investment appeal lies in its valuation metrics, such as a P/E of 14.57, and shareholder returns via dividends. Key risks include sensitivity to gold prices and execution of growth projects. The stock offers value for long-term investors despite current market weakness.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
